Phosphorylated STAT3 levels were initially decreased but strongly increased after sustained treatment with dasatinib, suggesting the existence of a compensatory feedback pathway that supports cancer cell survival by regulating STAT3 activity [132]. The gene discussed is STAT3; the disease is cancer.